Ocuphire Pharma announced the US Food and Drug Administration (FDA) has approved Ryzumvi (phentolamine ophthalmic solution) 0.75% eye drops for the treatment of pharmacologically induced mydriasis.
Pharmacologically induced pupil dilation can last up 24 hours, with side effects including photophobia and blurred vision, which may affect reading, working and driving, said Dr Jeffrey Nau, president of Ocuphire partner, Viatris Eye Care Division. “Our hope is that by addressing patient dilation barriers, we’re empowering eyecare professionals to broaden exam availability, leading to enhanced eye health outcomes.”
Ryzumvi was developed to also treat presbyopia and night vision disturbances. It is expected to be commercially available in the US in the first half of 2024.
